Boston Scientific officials are bullish that the company will grow sales by the end of the year, ending more than 2 year of sliding revenues.
A return to positive sales growth would end nearly 2.5 years of sliding revenues, and the medical device maker still has some rough patches to navigate, he said.
"In the 1st quarter we're still up against a difficult comparable for U.S. drug eluting stents, so we'll cycle through that. The 1st quarter will be challenging," Capello told us. "The 2nd quarter should be better."